CCR8 and neoplasm: LLC-OVA tumor-bearing mice were treated with Nb-Fc1A, which blocks CCR8 but cannot perform any Fc-mediated function (termed Anti-CCR8 (block) in the Figures), and with Nb-Fc1B, which also blocks CCR8 but mediates ADCC (termed Anti-CCR8 (ADCC)).